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ABSTRACT (Maximum 200
The goal of this research project is (a) designed to improve the quality of life by exploiting differences in the biochemical pharmacology of methotrexate (MTX) in MCF-7 breast cancer cells versus normal tissues and (b) provide one clear basis for intracellular rescue of only host cells from MTX toxicity when high dose MTX is used in combination with 5-fluorouracil (5-FU). The major findings are: (1) High dose MTX toxicity is reduced by a (priming -and non-toxic -)5-FU dose. 5-FU reverses high dose MTX acute toxicity on bone marrow. The erythroid cells appear to be more sensitive than the myeloid cells to the acute adverse effect of MTX. (2) A 50% reduction in the priming-dose of 5-FU was effective in providing marked protection against weight loss from an acute MTX dose 6 times the lethal dose. (3) Cytotoxicity to MCF-7 human breast cells may be the resultant of higher intracellular of methotrexate polyglutamate (MTX PGs) than MTX.
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Purpose and Scope of Subject Matter
The goal of this project is to use our previous experience to investigate research issues in protocol devlopment which impact upon the quality of life in breast cancer patients. There is a consensus that quality of life is amultidimensional construct, including at a minimum, disease and treatment related symptoms. Hence, this research project is (a) designed to improve the quality of life by exploiting differences in the biochemical pharmacology of MTX in MCF-7 and MDA-MB-436 breast cancer cells versus normal tissues and (b) provide one clear basis for intracellular rescue of only host cells from MTX toxicity when high dose MTX is used in combinatiion with 5-FU. Hence, an analysis of MTX and MTXPGs levels in MCF-7 breast cancer cells and subsequent effects on normal cells (bone marrow) were determined. Studies are in progress to define the optimal dose of MTX with respect to 5-FU by escalating the MTX dose. The parameters assessed are weight loss and survival.
Body
Experimental Methods, Assumptions, and Procedures Animals Female Balb/c mice weighing 18-22 g (approximate age 4-6 weeks) were obtained from Charles River Breeding Laboratories, Wilmington, MA. Upon arrival, mice were randomized and quarantined for at least one week. Animals were housed 5 per cage in a light (12 h/day), temperature (24°C), and humidity (60%) controlled room. Mice were given food and water ad libitum.
Toxicity Studies MTX, at a dose level of 250 mg/kg, was given as a single i.p. injection either alone or various combinations of 25 mg/kg of 5-FU. 0.9% NaCl (sterile) was administered as a vehicle control. Animals surviving 3-14 days after a priming dose of 5-FU administered 2h prior to MTX, MTX given 2h prior to 5-FU, MTX, 5-FU, and control were anesthetized and blood collected by cardiac puncture in tubes containing EDTA for erythrocyte and leukocyte determination. After euthanasia, bone marrow was harvested by splitting the femur with a no. 11 scapel blade. Direct imprints of the exposed bone marrow cells were made on glass slides. Glass slides were the fixed in a methanolic solution, stained with an azo dye and followed by equilibration in an alkaline solution of the azo dye. The myeloid-erythroid ratio from bone marrow was determined by counting a minimum of 500 cells. In separate studies from above, MTX at a dose level of 1250 mg/kg (6 times the lethal dose) and 5-FU at a dose of 12 mg/kg (a 50% reduction in the non-toxic dose) were evaluated to determine the the minimum 5-FU dose that will affect a very high MTX dose. Animals were observed for weight loss and mortality.
Cells and Measurement of Intracellular MTX and MTXPGs MCF-7 breast cancer cells were grown in monolayer culture in Dulbecco's modified Eagles medium DMEM) containing 5% donor calf serum, 100 unit/ml of penicillin, 100 mg streptomycin, and 10 microgram/ml of insulin. Stock cultures were maintained in 75-cm 2 flasks and incubation at 37°C. Cell populations were serially passed every 3 to 5 days. Breast cancer cells were harvested with 5 ml of a trypsin-EDTA solution containing 0.5 g of trypsin and 0.2 g of EDTA/liter and 1 x 10 4 cells were passed in 1 ml of DMEM at 1000 x g. Cells were grown for 72h in an atmosphere of 5% C0 2 in air (8), 0.7 fjM MTX was added to the growing cells for 48h. MTX and MTXPGs were separated by using a paired ion HPLC system. Samples were injected onto a /^-Bondapak C lg reverse-phase column. Solvent A consisted of 10 mM potassium dihydrogen phosphate, pH 7.0 containing 10 mM tetrabutylammoniumhydrogen sulfate and solvent B consisted of methanol. The retention times of MTX and MTXPGs were determined the absorbance of the effluent the effluent at 254 nm. MTXPG2, MTXPG3 and MTXPG4 standards were custom synthesized by Moreavak Biochemicals, Brea, CA.
Results and Discussion
When cell extracts containing MTX were subjected to analysis by HPLC, peaks were detected which corresponded to standard MTXPG2, MTXPG3 and MTXPG4 (8) . At a cell density of 10\ the MTX, MTXPG2, MTXPG3, and MTXPG4 cellular levels, respectively, were 20.5, 7.3, 11.4, and 15.8. Since MTXPGs are in a greater amount than MTX, MTXPGs inhibitory effect should be sustained and longer than MTX as a result of MTXPGs cellular retention. Similar studies should be done to those which defined the relative amounts of MTX and MTXPGs (if any) in sensitive normal tissue such as bone marrow and gastrointestinal tissue. Figure 1 illustrates the effect of an acute administration of high dose MTX (250 mg / kg) and 5-FU (25 mg / kg) on bone marrow. A comparison is made between a priming dose of 5-FU administered 2 h before MTX vs. MTX only, 5-FU, and control bone marrow (myeloid : erythroid ratio). A marked increase in the myeloid : erythroid ratio occured in animals receiving MTX and 5-FU (2h) before MTX when compared only to 5-FU and control. However, a significant decrease in the myeloid : erythroid ratio occured when 5-FU (2h) before MTX is compared to MTX. There is no effect on peripheral blood from the acute administration of these agents.
A further manifestatioin of MTX toxicity is weight loss. To determine the lowest priming-and non-toxic dose of 5-FU which would have an effect on an extremely high dose of MTX, animals were administered 13 mg/kg of 5-FU and 1250 mg/kg of MTX. As shown in Fig. 2 , extreme weight loss occured in all animals receiving MTX, with the most extreme loss occuring in MTX and MTX (2h) before 5-FU treated animals. In contrast to animals receiving only MTX or MTX (2h) before 5-FU, less weight loss results from the usage of a priming-and low non-toxic dose of 5-FU when given 2h before MTX administration. The maximum weight reduction after MTX, MTX (2h) before 5-FU, and a priming-and low non-toxic 5-FU dose 2h before MTX administration, respectively, is 3.5 g, 2.9 g, and 2.1 g. Whereas, animals treated with 5-FU alone loss only 0.3 g of body weight; and non-treated (saline-treated; control) animals loss no weight. All animals receiving 1250 mg/kg of MTX survived for 5 days.
Conclusions
The studies reported here indicate that the toxicity of very high dose MTX on bone marrow and animal body weight was greatest when MTX was administered alone and when MTX administration a non-toxic dose of 5-FU. These results suggest that the incidence and severity of MTX 2h before 5-FU toxicity is best related to MTX rather than 5-FU since 5-FU had no effect which differed significantly from control. A priming-and non-toxic-dose of 5-FU reverses high dose MTX acute effects on bone marrow. The erythroid cells 1) appear to be more sensitve than the myeloid cells to the acute adverse effect of MTX and 2) show marked protection by a priming and non-toxic dose 
